If Humira, the drug that treats a range of autoimmune conditions, were its own company, it would have almost the same amount of annual sales as Southwest Airlines or Visa and would be more than twice the size of the Hilton global hotel chain.
The big picture: AbbVie has several other drugs, but Humira is its financial bread and butter. Humira's sales likely will decline this year as more biosimilar versions hit European markets, but the drug will still rake in more revenue in the U.S. as its net annual price exceeds $40,000.
Go deeper: The drug pricing maze